AVX 001

Drug Profile

AVX 001

Alternative Names: AKH-217; AVX-001

Latest Information Update: 29 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avexxin
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Immunomodulators; Phospholipase A2 modulators; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Plaque psoriasis

Most Recent Events

  • 29 Dec 2016 Avexxin completes a phase II trial in Atopic dermatitis (In adolescents, In adults, In the elderly) in Denmark (Topical) (EudraCT2016-003013-96)
  • 28 Sep 2016 Phase-II clinical trials in Atopic dermatitis (In adolescents, In adults, In the elderly) in Denmark (Topical) (EudraCT2016-003013-96)
  • 02 Jul 2015 Avexxin completes a phase-I/II trial in Psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top